<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525326</url>
  </required_header>
  <id_info>
    <org_study_id>SHENKANG2020XU</org_study_id>
    <nct_id>NCT04525326</nct_id>
  </id_info>
  <brief_title>Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases</brief_title>
  <official_title>A Prospective Study on the Conversion Therapy of Ras / BRAF Wild Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases: Standard Chemotherapy Plus Cetuximab VS. Standard Chemotherapy Plus Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prognosis of patients with metastatic right-sided colon cancer is worse than that of&#xD;
      patients with metastatic left-sided cancer. Different guidelines have different&#xD;
      recommendations on specific conversion therapy for colorectal liver metastases. The United&#xD;
      States NCCN guidelines do not recommend standard chemotherapy combined with anti EGFR&#xD;
      monoclonal antibody for patients with right colon cancer. The European ESMO guidelines&#xD;
      recommend that patients with Ras / BRAF wild-type right-sided colon cancer should first&#xD;
      consider three drugs ± bevacizumab, but considering the objective response rate results,&#xD;
      standard chemotherapy + anti EGFR monoclonal antibody is still one of the choices. China CSCO&#xD;
      guidelines recommend standard chemotherapy ± bevacizumab, and also recommend standard&#xD;
      chemotherapy + cetuximab for patients with right-sided colon cancer.&#xD;
&#xD;
      Therefore, the targeted therapy for RAS / BRAF wild-type metastatic right colon cancer is&#xD;
      still controversial. Therefore, we are ready to carry out the clinical trial of cetuximab and&#xD;
      bevacizumab in conversion therapy for RAS / BRAF wild-type metastatic right colon cancer. The&#xD;
      conversion resection rate is the primary point, and the objective response rate,&#xD;
      perioperative safety and long-term survival are the secondary points.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conversion liver resection rate</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Rate of conversion from initially unresectable liver metastases to resectable ones</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>up to 6 months</time_frame>
    <description>rate of objective response for therapy(according to RECIST 1.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Incidence of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">584</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>standard chemotherapy plus Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>standard chemotherapy plus Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>mFOLFOX+Cetuximab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis</description>
    <arm_group_label>standard chemotherapy plus Cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>mFOLFOX+Bevacizumab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis</description>
    <arm_group_label>standard chemotherapy plus Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX/FOLFIRI ( Standard Chemotherapy)</intervention_name>
    <description>Standard Chemotherapy</description>
    <arm_group_label>standard chemotherapy plus Bevacizumab</arm_group_label>
    <arm_group_label>standard chemotherapy plus Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The primary tumor was confirmed by histology as colorectal adenocarcinoma&#xD;
&#xD;
          2. primary right-sided colorectal adenocarcinoma&#xD;
&#xD;
          3. Radiologic evidence suggests that the initial unresectable liver metastases&#xD;
&#xD;
          4. RAS/BRAF gene wild-type states&#xD;
&#xD;
          5. ECOG was 0 ~ 1&#xD;
&#xD;
          6. Life expectancy ≥ 3 months&#xD;
&#xD;
          7. Good hematological function: neutrophil ≥ 1.5x109/l and platelet count ≥ 100x109 / L;&#xD;
             HB ≥ 9g / dl (within one week before randomization)&#xD;
&#xD;
          8. Normal liver and kidney function: serum bilirubin ≤ 1.5x normal upper limit (ULN),&#xD;
             alkaline phosphatase ≤ 5x ULN, serum transaminase (AST or ALT) ≤ 5x ULN (within one&#xD;
             week before randomization);&#xD;
&#xD;
          9. Sign the written informed consent to participate in the experiment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with liver metastases from colorectal cancer who have previously received&#xD;
             targeted therapy, chemotherapy, radiotherapy or interventional therapy&#xD;
&#xD;
          2. Known or suspected extrahepatic metastasis&#xD;
&#xD;
          3. Patients with known hypersensitivity to any component of the study treatment&#xD;
&#xD;
          4. Clinical related coronary heart disease or history of myocardial infarction in the&#xD;
             last 12 months or left ventricular ejection fraction below normal range&#xD;
&#xD;
          5. Acute or subacute intestinal obstruction&#xD;
&#xD;
          6. Pregnancy (no pregnancy confirmed by serum / urine β - hCG) or breastfeeding.&#xD;
&#xD;
          7. She had other malignant tumors within 5 years, except for those with skin basal cell&#xD;
             carcinoma or cervical cancer&#xD;
&#xD;
          8. Known drug / alcohol abuse&#xD;
&#xD;
          9. No legal capacity or limited legal capacity&#xD;
&#xD;
         10. There is peripheral neuropathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 23, 2020</last_update_submitted>
  <last_update_submitted_qc>August 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cetuximab</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Liver Metastases</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>right-sided</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

